Impact of Measurable Residual Disease Status on Outcomes After HLA-Matched Donor Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
Pretransplant MRD status predicts post-allo-HCT outcomes, with MRD positivity associated with reduced overall and disease-free survival and increased relapse risk. Personalized MRD-directed strategies are needed to optimize outcomes in AML patients undergoing allogeneic transplantation.
Authors
- Mehdi Hamadani (ORCID: https://orcid.org/0000-0001-5372-510X)
- Muhammad Kashif Amin (ORCID: https://orcid.org/0000-0002-4052-7339)
- Anurag K. Singh (ORCID: https://orcid.org/0000-0003-1114-9508)
- Haitham Abdelhakim
- Muhammad Umair Mushtaq (ORCID: https://orcid.org/0000-0001-8122-0563)
- Raheel Iftikhar
- Joseph P. McGuirk (ORCID: https://orcid.org/0000-0002-0539-4796)
- Matthew McGuirk
- R. Laila Ahsan
- Sibgha Gull Chaudhary
- Moazzam Shahzad (ORCID: https://orcid.org/0000-0002-9609-6160)
- Iqra Anwar
- Abhinav Vyas
- Sohaib Irfan (ORCID: https://orcid.org/0009-0008-3133-5993)
Institutions
- Medical College of Wisconsin (US)
- Moffitt Cancer Center (US)
- University of Kansas Medical Center (US)
- Cellular Therapeutics (United Kingdom) (GB)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1016/j.clml.2025.08.011
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medical College of Wisconsin
- Health Resources and Services Administration
- U.S. Public Health Service
- National Heart, Lung, and Blood Institute
- Office of Naval Research
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases